Chronotherapeutics: the relevance of timing in cancer therapy
- PMID: 16596317
- DOI: 10.1007/s10552-005-9004-7
Chronotherapeutics: the relevance of timing in cancer therapy
Abstract
Background: Cell physiology is regulated along the 24-h time scale by a circadian timing system composed of molecular clocks within each cell and a central coordination system in the brain. The mammalian molecular clock is made of interconnected molecular loops involving at least 12 circadian genes. The cellular clocks are coordinated by the suprachiasmatic nuclei, a hypothalamic pacemaker which also helps the organism adjust to environmental cycles. The rest-activity rhythm is a reliable marker of the circadian system function in both rodents and man. This circadian organization is responsible for predictable changes in the tolerability and efficacy of anticancer agents, and possibly also in tumor promotion or growth.
Methods: Expected least toxic times of chemotherapy were extrapolated from experimental models to human subjects with reference to the rest-activity cycle. The clinical relevance of the chronotherapy principle, i.e. treatment administration as a function of rhythms, has been demonstrated in randomized multicenter trials.
Results: Chronotherapeutic schedules have been used to safely document the activity of the association of oxaliplatin, 5-FU and leucovorin against metastatic colorectal cancer and to set up a new medicosurgical management of this disease which achieved unprecedented long term survival.
Conclusion: The chronotherapy concept offers further promises for improving current cancer treatment options as well as for optimizing the development of new anticancer or supportive agents.
Similar articles
-
Cancer chronotherapy: principles, applications, and perspectives.Cancer. 2003 Jan 1;97(1):155-69. doi: 10.1002/cncr.11040. Cancer. 2003. PMID: 12491517 Review.
-
The circadian timing system, a coordinator of life processes. implications for the rhythmic delivery of cancer therapeutics.Conf Proc IEEE Eng Med Biol Soc. 2006;Suppl:6736-9. doi: 10.1109/IEMBS.2006.260934. Conf Proc IEEE Eng Med Biol Soc. 2006. PMID: 17959499 Review.
-
Circadian chronotherapy for human cancers.Lancet Oncol. 2001 May;2(5):307-15. doi: 10.1016/S1470-2045(00)00326-0. Lancet Oncol. 2001. PMID: 11905786 Review.
-
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.Adv Drug Deliv Rev. 2007 Aug 31;59(9-10):1015-35. doi: 10.1016/j.addr.2006.11.001. Epub 2007 Jul 4. Adv Drug Deliv Rev. 2007. PMID: 17692427 Review.
-
[Chronopharmacology and chronotherapy of cancers].Pathol Biol (Paris). 1996 Sep;44(7):631-44. Pathol Biol (Paris). 1996. PMID: 8977920 Review. French.
Cited by
-
Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.Curr Oncol. 2012 Apr;19(2):e75-83. doi: 10.3747/co.19.879. Curr Oncol. 2012. PMID: 22514500 Free PMC article.
-
Improving therapeutic ratio in head and neck cancer with adjuvant and cisplatin-based treatments.Biomed Res Int. 2013;2013:817279. doi: 10.1155/2013/817279. Epub 2013 Dec 19. Biomed Res Int. 2013. PMID: 24455727 Free PMC article.
-
Temporal variation in the recovery from impairment in adriamycin-induced wound healing in rats.J Circadian Rhythms. 2007 Oct 10;5:6. doi: 10.1186/1740-3391-5-6. J Circadian Rhythms. 2007. PMID: 17927815 Free PMC article.
-
Healthy clocks, healthy body, healthy mind.Trends Cell Biol. 2010 Jan;20(1):36-44. doi: 10.1016/j.tcb.2009.10.005. Epub 2009 Nov 16. Trends Cell Biol. 2010. PMID: 19926479 Free PMC article. Review.
-
Personalized Drug Dosage - Closing the Loop.Pharm Res. 2017 Aug;34(8):1539-1543. doi: 10.1007/s11095-016-2076-0. Epub 2016 Dec 9. Pharm Res. 2017. PMID: 27943015 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources